Work

Abstract CT248: Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF- and NRAS-mutation positive solid tumors

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct248

Authors: Meredith McKean, Cesar A. Perez, Shumei Kato, Alexander I. Spira, Yan Xing, Hao Xie, Michael Millward, Anthony Olszanski, Ken Kobayashi, Nichol Miller, Paul Severson, Betty Tam, Caro Unger

Institutions: Sarah Cannon, Sylvester Comprehensive Cancer Center, University of California San Diego, Virginia Cancer Specialists, City Of Hope National Medical Center, Moffitt Cancer Center, Fox Chase Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282932695

Cites:

Cited by:

Related to: 10